The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New spin-out company

26 Nov 2014 07:00

RNS Number : 9910X
Frontier IP Group plc
26 November 2014
 



 

 

AIM: FIPP

 

Frontier IP Group plc

("Frontier IP" or "the Company")

 

New Spin-out Company - Cambridge Simulation Solutions Limited

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce that it has received a stake in Cambridge Simulation Solutions Ltd ("Cambridge Simulation"), a spin-out company from the Department of Chemical Engineering and Biotechnology at the University of Cambridge (the "Department").

Frontier IP has entered into an agreement with Cambridge Simulation in which it provides advisory and business development services in return for which it has received a 40% equity stake in the new spin-out. Cambridge Simulation has been formed to exploit the technology developed by Dr. Vassilios Vassiliadis, a Senior Lecturer at the Department. Dr. Vassiliadis has developed a method to simulate and control complex chemical processes and Frontier IP's role will be to support the licensing and commercialisation of this technology, which potentially has a wide range of commercial applications in industry, including the food and pharmaceutical sectors.

The Department of Chemical Engineering and Biotechnology at the University of Cambridge is a leading global research department, with Chemical Engineering ranked the best in the world outside the US and 4th in the world including the US (QS World University Rankings by Subject 2014). Working effectively with industry is a core strength of the Department, as is progressing novel technologies through spinout companies and licensing agreements to ultimate launch of marketed products.

Neil Crabb, Chief Executive of Frontier IP, said,

"This collaboration with Dr. Vassilios Vassiliadis represents an exciting new opportunity for Frontier IP. We have in-depth experience in commercialising IP and we look forward to working with Dr. Vassiliadis and the Department of Chemical Engineering and Biotechnology at the University of Cambridge to maximise the potential of the existing and the upcoming IP."

Dr. Vassiliadis, said,

"The aim of Cambridge Simulation is to produce a rapid integrator engine suitable for a range of applications and industries, including Chemical Engineering, Biotechnology, Biomedical, Pharmaceuticals, Aerospace and Microelectronics. I'm delighted to be entering into this collaboration with Frontier IP."

Professor Nigel Slater at the Department of Chemical Engineering and Biotechnology at the University of Cambridge, said,

"The Department of Chemical Engineering and Biotechnology at the University of Cambridge fuses leading-edge biotechnology research with chemical engineering skills within an ethos of commercial awareness and exploitation. Broadly, our research strategy targets sustainable reaction engineering, product engineering and healthcare and the Department's activities are structured to provide novel solutions to these challenges. I welcome the launch of this company, as an example of the Department's innovative spirit in tackling the issues of our time."

Enquiries

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

Mark Percy / Catherine Leftley, Corporate Finance

David Banks / Paul Jewell, Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Jon Levinson / Lucy Williams

KTZ Communications

T: 020 3178 6378

Katie Tzouliadis / Deborah Walter

 

 

 

 

Notes to Editor:

 

Frontier IP Group plc ("Frontier IP") specialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes. www.frontierip.co.uk.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMMZMNKLGDZM
Date   Source Headline
29th Jul 20209:11 amRNSHolding(s) in Company
28th Jul 20205:22 pmRNSHolding(s) in Company
22nd Jul 202012:50 pmRNSHolding(s) in Company
21st Jul 20209:05 amRNSSecond Price Monitoring Extn
21st Jul 20209:00 amRNSPrice Monitoring Extension
21st Jul 20207:00 amRNSResult of Capital Raising
20th Jul 20204:37 pmRNSPrimaryBid.com Offer
20th Jul 20204:35 pmRNSProposed Capital Raising of a minimum of £2m
20th Jul 20202:00 pmRNSCambridge Raman Imaging completes £250,000 funding
14th Jul 20207:00 amRNSAquaInSilico wins grant to commercialise software
13th Jul 20207:00 amRNSPulsiv demonstrates strong progress
7th Jul 20207:00 amRNSCelerum supports development for PlanSea Solutions
6th Jul 20207:00 amRNSBosch collaboration with Fieldwork
30th Jun 20205:00 pmRNSTotal Voting Rights
23rd Jun 20207:00 amRNSThe Vaccine Group: strong COVID-19 progress
17th Jun 20207:00 amRNSCambridge & FIPP collaborate to tackle gum disease
28th May 20207:10 amRNSPortfolio news: Access to Elute's Patent Reader
28th May 20207:00 amRNSExercise of Options and Total Voting Rights
26th May 20207:00 amRNSPortfolio news – Exscientia raises $60 million
7th May 20207:00 amRNSExscientia and SRI International collaborate
1st May 20207:00 amRNSPortfolio news – Molendotech raises £425,000
15th Apr 20207:00 amRNSPortfolio news – Pulsiv Solar awarded patent
9th Apr 20207:00 amRNSPortfolio news: Alusid launches luxury Block range
6th Apr 202012:01 pmRNSHolding(s) in Company
1st Apr 20207:00 amRNSExscientia announces joint initiative re COVID-19
30th Mar 20204:40 pmRNSSecond Price Monitoring Extn
30th Mar 20204:36 pmRNSPrice Monitoring Extension
30th Mar 20207:00 amRNSElute Intelligence’s AI to back COVID-19 research
26th Mar 20207:00 amRNSPortfolio news: new portfolio company AquaInSilico
25th Mar 20207:00 amRNSUnaudited Half Year Results
19th Mar 20207:00 amRNSFrontier partners University of Lisbon competition
17th Mar 20203:15 pmRNSNotice of interim results
13th Mar 20207:00 amRNSPortfolio news – The Vaccine Group Update
12th Mar 202011:05 amRNSSecond Price Monitoring Extn
12th Mar 202011:00 amRNSPrice Monitoring Extension
19th Feb 202012:37 pmRNSHolding(s) in Company
17th Feb 20207:00 amRNSCRIL wins EUR140,000 EU Graphene Flagship funding
12th Feb 20207:00 amRNSPortfolio news - FIPP increases stake in Celerum
31st Jan 20207:00 amRNSPortfolio news - Exscientia
20th Jan 20207:00 amRNSPortfolio news - The Vaccine Group raises £680,000
16th Jan 20203:28 pmRNSHolding(s) in Company
14th Jan 20207:00 amRNSFieldwork Robotics secures first equity funding
10th Jan 20207:00 amRNSExscientia enters collaboration with Bayer AG
31st Dec 20191:00 pmRNSTotal Voting Rights
16th Dec 201910:36 amRNSExercise of Options and Issue of Equity
11th Dec 20196:03 pmRNSHolding(s) in Company
9th Dec 20193:25 pmRNSHolding(s) in Company
9th Dec 20193:21 pmRNSHolding(s) in Company
9th Dec 20192:08 pmRNSHolding(s) in Company
9th Dec 20199:46 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.